Print this page    •   Back to Web version of article

Nevirapine Precautions Published

February 27, 2004

Physicians starting patients on nevirapine (Viramune®) need to be aware of new precautions published in February 2004 by Boehringer Ingelheim. A nevirapine combination is recommended as an "alternative" antiretroviral starting regimen in the current U.S. treatment guidelines,1 but may be the best starting regimen for some patients -- for example, because of its favorable effect in raising HDL ("good cholesterol"). The new warning is paradoxically good news, because it helps avoid problems with nevirapine, including identifying which patients should use it very cautiously or not at all. For example, women with a CD4+ count above 250 have a 12 times greater risk of liver toxicity than other patients. And patients need special monitoring when they start nevirapine treatment, because the risk of problems is greatest then.

For more information see the following at:


Reference

  1. www.aidsinfo.nih.gov/guidelines/.


ISSN # 1052-4207

Copyright 2004 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.


Back to the AIDS Treatment News February 27, 2004 contents page.




This article was provided by AIDS Treatment News. It is a part of the publication AIDS Treatment News. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art31721.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.